Navigation Links
In Vitro Study of Adamas Pharmaceuticals' Triple Combination Antiviral Drug Therapy Shows Activity Against Drug-Resistant Influenza Viruses
Date:9/13/2009

ta were presented on September 13, 2009 at 10:45 am. ICAAC will also feature the Adamas study at a press conference at 8:30 a.m. Monday, September 14, 2009. Reporters unable to attend the meeting or press conference can watch it live at http://www.ustream.tv/channel/49th-icaac.

About TCAD

Adamas is pioneering triple-combination antiviral drug (TCAD) therapy for influenza, which is designed to inhibit viral replication at multiple points during the virus life cycle. TCAD therapy includes Adamas' investigational proprietary fixed-dose combination of amantadine and ribavirin, to be administered adjunctively with a neuraminidase inhibitor such as Tamiflu (oseltamivir phosphate, Roche). Preclinical data indicate that the in vitro combination of these drugs, each with their own mechanism of action, acts synergistically to provide a much higher level of antiviral activity than single or double drug combinations. In in vitro studies to date, TCAD therapy also has been found to provide greater antiviral activity across multiple strains of influenza, even those resistant to single pharmaceutical agents. Adamas is accelerating development of its TCAD therapy for influenza A by conducting a Phase 2 clinical trial in the Southern Hemisphere where the novel influenza A/H1N1 pandemic is active, and is preparing to initiate a clinical study of TCAD therapy for influenza A in North America during this upcoming flu season.

About Adamas

Adamas is an emerging pharmaceutical company focused on developing small molecule, Advantaged Therapeutics(TM) to treat neurological and infectious diseases, including influenza A, the cause of the current flu pandemic. Adamas' approach to pharmaceutical development is to identify synergistic drug mechanisms that can be developed as optimized
'/>"/>

SOURCE Adamas Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Georgia Reproductive Specialists Participates in Largest-Ever In Vitro Fertilization Clinical Trial in the World
2. Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria
3. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
4. Oritavancin Demonstrates Potent and Rapid In Vitro Activity Against MRSA, VRE and Other Strains of Resistant Bacteria
5. MatTeks EpiDerm In Vitro Tissues Headed for Validation in Europe
6. Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor
7. New Data Show In Vitro Potency of Doripenem Against Resistant Bacteria
8. Tobira Therapeutics Inc. Announces In Vitro Data of TBR-652 for the Treatment of HIV
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... NEW YORK , Aug. 1, 2014 /PRNewswire/ ... , the largest, independent manufacturer of phosgene and ... , today announced that it has acquired Framochem ... based in Hungary . ... product offerings and creates one of the world,s ...
(Date:8/1/2014)... LAKE FOREST, Ill. , Aug. 1, 2014 ... private equity firm focused exclusively on the healthcare ... Inc. ("Vesta") to The Lubrizol Corporation ("Lubrizol"). Lubrizol, ... company that produces and supplies technologies to customers ... Terms of the transaction were not disclosed. ...
(Date:8/1/2014)... , Aug. 1, 2014 ... of the "Global Medical Biosensors Market 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 Medical biosensors ... help of physicochemical detectors. These biosensors monitor health ... invasive and non-invasive methods. They are cost-effective and ...
Breaking Medicine Technology:VanDeMark Chemical Inc. Acquires Framochem 2VanDeMark Chemical Inc. Acquires Framochem 3VanDeMark Chemical Inc. Acquires Framochem 4RoundTable Healthcare Partners Announces Sale of Vesta Funding, Inc. to The Lubrizol Corporation 2Global Medical Biosensors Market 2014-2018: Key Vendors are Abbott, Bayer, LifeScan and F. Hoffmann-La Roche 2
... Jan. 18 ,Exelixis, Inc. (Nasdaq: EXEL ) ... exercise its option to license XL784 for further,development ... meet its primary endpoint in a phase 2 ... in one subgroup were encouraging,Exelixis believes that the ...
... Specialty Pharmacy, one,of the largest privately owned national ... an agreement with Genzyme Corporation to,administer their 2008 ... the world,s largest biotechnology companies dedicated to products,and ... transplant, and oncology., Diplomat will be the ...
Cached Medicine Technology:GSK Does Not Option XL784 for Further Development 2GSK Does Not Option XL784 for Further Development 3Genzyme Corporation Selects Diplomat Specialty Pharmacy for 2008 Renagel Medicare Part D Assistance Program 2
(Date:8/1/2014)... August 01, 2014 Stryker hip ... of the 2012 Rejuvenate and ABG II Modular-Neck ... New Jersey’s Bergen County Superior Court, Bernstein Liebhard ... proceeding, the Court has issued a Final ... and all hard copy and electronic materials produced ...
(Date:8/1/2014)... 01, 2014 Summer is here, and with ... during the summer, and they can be a pain for ... to help all their customers get rid of ticks and ... 6,000 eggs in the summer, which is why they are ... tall grass and woodland areas and carry a number of ...
(Date:8/1/2014)... The American Telemedicine Association (ATA) lauds ... Peter Welch (D-VT), for their latest actions to ... of 2014, which improves telemedicine coverage in Medicare. ... healthcare access and affordability using telecommunications technology," said ... cost-saving provisions are critical to improve telehealth coverage ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 The ... others such as Zinc Oxide, Titanium Dioxide, and ... Building & Construction, Food & Beverages, Textiles, and ... ROW) - Global Trends and Forecasts to 2018" ... market drivers, opportunities, and trends in the diverse ...
(Date:8/1/2014)... August 01, 2014 The North America ... security solutions market in North America with analysis and ... from around $3.53 billion in 2014 to $4.77 billion ... to 2019. , Browse through the TOC of the ... idea of the in-depth analysis provided. It also provides ...
Breaking Medicine News(10 mins):Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 2Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 3Health News:Tis the Season for Tick Prevention 2Health News:ATA Applauds Bill on Medicare Telemedicine Improvements 2Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 2Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 3Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 4Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 2Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 3Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 4
... Taking menstrual cycle into account when booking exam may cut ... (HealthDay News) -- Using a blood test to pinpoint the ... menstrual cycles could reduce the need for repeat scans, U.S. ... MRI scans during the follicular phase (days 3 to14) of ...
... simple blood test corresponding to the follicular phase (days ... optimal scheduling of breast MRI exams in premenopausal women ... repeat scans and non-diagnostic tests patients experience and providing ... to a study published in the December issue of ...
... Virginia Commonwealth University Massey Cancer Center and VCU Institute ... may play a pivotal role in two processes that ... metastasis. Scientists hope the finding could lead to an ... this gene resulting in inhibition of cancer growth. ...
... alcohol dependence problems drink significantly more than do younger adults ... The findings suggest that older problem drinkers may have developed ... than younger abusers to achieve the effects they seek. ... 60 who have alcohol dependence drink more than 40 alcoholic ...
... , NORTHBROOK, Ill., Nov. 20 ... one of the fastest growing cosmetic skin care providers ... injections, Zerona(TM) laser treatments and SmartLipo(TM) body contouring at ... cosmetics industry, new innovations and technologies are constantly being ...
... Mallika Chopra, healthy living expert and founder and CEO ... products in the US, are teaming up to help Americans ... with advice from Chopra, to be posted today on Intent.com. ... the stress or foreboding that typically comes with this time ...
Cached Medicine News:Health News:Blood Test Could Boost Clarity of Breast MRI Results for Some 2Health News:Researchers identify role of gene in tumor development, growth and progression 2Health News:Older problem drinkers use more alcohol than do their younger counterparts 2Health News:Nu U Medspa to Offer Dysport, Zerona, SmartLipo at HealthySkinPortal.com 2Health News:Nu U Medspa to Offer Dysport, Zerona, SmartLipo at HealthySkinPortal.com 3Health News:Survive and Thrive This Holiday Season with Rescue Remedy and Advice from Mallika Chopra 2Health News:Survive and Thrive This Holiday Season with Rescue Remedy and Advice from Mallika Chopra 3
... Bird and Cronin, ... manufacturer of Patient Footwear, ... Patient Care Products. Our ... highest quality and available ...
Perfect for use in the E.R. Stabilizes collateral ligament strains in seconds and allows hand and finger function. Made from 1/8" AliPlast™ PXE. Can be scissor trimmed....
... Control of thumb motion can be difficult ... for persons with spinal cord injuries and ... to cerebral palsy or other motor or ... the thumb for control and coordination. Soft ...
... ThumWrap Splints offer support without the restriction ... mild pain or strain due to repetitive ... the rigid or the flexible stay to ... Washable and breathable, the ThumWrap Splint is ...
Medicine Products: